Jian Zhong, Chen Yi-Je, Shimkunas Rafael, Jian Yuwen, Jaradeh Mark, Chavez Karen, Chiamvimonvat Nipavan, Tardiff Jil C, Izu Leighton T, Ross Robert S, Chen-Izu Ye
Department of Pharmacology, University of California Davis, Davis, California, United States of America.
Microsurgery Core of Department of Pharmacology, University of California Davis, Davis, California, United States of America.
PLoS One. 2016 Aug 8;11(8):e0160605. doi: 10.1371/journal.pone.0160605. eCollection 2016.
Isolation of high quality cardiomyocytes is critically important for achieving successful experiments in many cellular and molecular cardiology studies. Methods for isolating cardiomyocytes from the murine heart generally are time-sensitive and experience-dependent, and often fail to produce high quality cells. Major technical difficulties can be related to the surgical procedures needed to explant the heart and to cannulate the vessel to mount onto the Langendorff system before in vitro reperfusion can begin. During this period, transient hypoxia and ischemia may damage the heart, resulting in low yield and poor quality of cells, especially for heart disease models that have fragile cells. We have developed novel in vivo cannulation methods to minimize hypoxia and ischemia, and fine-tuned the entire protocol to produce high quality ventricular myocytes. The high cell quality has been confirmed using important structural and functional criteria such as morphology, t-tubule structure, action potential morphology, Ca2+ signaling, responsiveness to beta-adrenergic agonist, and ability to have robust contraction under mechanically loaded condition. Together these assessments show the preservation of the cardiac excitation-contraction machinery in cells isolated using this technique. The in vivo cannulation method enables consistent isolation of high-quality cardiomyocytes, even from heart disease models that were notoriously difficult for cell isolation using traditional methods.
在许多细胞和分子心脏病学研究中,分离高质量的心肌细胞对于成功开展实验至关重要。从小鼠心脏分离心肌细胞的方法通常对时间敏感且依赖经验,并且常常无法获得高质量的细胞。主要技术难题可能与在体外再灌注开始前取出心脏并插管至血管以安装到Langendorff系统所需的手术操作有关。在此期间,短暂的缺氧和缺血可能会损害心脏,导致细胞产量低且质量差,尤其是对于细胞脆弱的心脏病模型而言。我们开发了新型的体内插管方法以尽量减少缺氧和缺血,并对整个方案进行了微调以产生高质量的心室肌细胞。已使用重要的结构和功能标准(如形态、横管结构、动作电位形态、Ca2+信号传导、对β-肾上腺素能激动剂的反应以及在机械负荷条件下进行有力收缩的能力)证实了细胞的高质量。这些评估共同表明,使用该技术分离的细胞中保留了心脏兴奋-收缩机制。这种体内插管方法能够一致地分离出高质量的心肌细胞,即使是对于使用传统方法进行细胞分离 notoriously difficult(此处原文有误,可理解为“极其困难”)的心脏病模型也是如此。